<p>不幸的是，对于一些股东来说，<strong>Cresco Labs Inc.</strong>（CSE:CL）的股价在过去三十天内暴跌了 37%，延续了近期的痛苦。在过去的 30 天里，股价的下跌使得股东们经历了艰难的一年，股价在此期间下跌了 37%。</p>
<p>在价格大幅下跌之后，Cresco Labs 目前可能发出看涨信号，其市销率（&#34;P/S&#34;）为 0.4 倍，因为在加拿大制药行业中，几乎一半的公司市销率超过 1 倍，甚至市销率高于 3 倍的情况也并不罕见。尽管如此，我们需要更深入地挖掘，以确定降低的市销率是否有合理的依据。</p>
<p>特朗普承诺要&#34;释放&#34;美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
<p>查看我们对 Cresco Labs 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/273639073-ps-multiple-vs-industry-1-dark-2/1764162132640?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/273639073-ps-multiple-vs-industry-1-dark-2/1764162132640"/></p>
<p>CNSX:CL 市销率与行业比较 2025 年 11 月 26 日</p>
<h3>Cresco Labs 最近的表现如何？</h3>
<p>尽管该行业最近经历了收入增长，但 Cresco Labs 的收入却出现了下滑，这并不好。市销率可能较低是因为投资者认为这种糟糕的收入表现不会有所改善。如果你仍然喜欢这家公司，你会希望情况不是这样，以便你可以在它不受欢迎时买入一些股票。</p>
<p>想要了解分析师对公司的完整预测吗？那么我们 <strong>免费的</strong>Cresco Labs 报告将帮助你揭示未来的趋势。</p>
<h2>Cresco Labs 是否有收入增长的预测？</h2>
<p>Cresco Labs 的市销率对于一家预计仅能实现有限增长的公司来说是典型的，重要的是，其表现还低于行业水平。</p>
<p>在回顾过去一年的财务数据时，我们感到沮丧，因为公司的收入下降了 9.8%。过去三年的表现也不理想，因为公司总共缩减了 21% 的收入。因此，可以公平地说，最近的收入增长对公司来说是不可取的。</p>
<p>展望未来，预计未来三年每年将实现 0.4% 的增长，这是八位分析师对公司的估计。同时，行业的其余部分预计每年将扩张 5.8%，这显然更具吸引力。</p>
<p>根据这些信息，我们可以理解为什么 Cresco Labs 的市销率低于行业水平。似乎大多数投资者预计未来增长有限，因此只愿意为该股票支付较低的价格。</p>
<h2>我们可以从 Cresco Labs 的市销率中学到什么？</h2>
<p>Cresco Labs 的市销率随着其股价的下跌而下降。一般来说，我们倾向于将市销率的使用限制在评估市场对公司整体健康状况的看法上。</p>
<p>我们已经确定 Cresco Labs 维持其低市销率是因为其预测增长低于更广泛的行业，正如预期的那样。在这个阶段，投资者认为收入改善的潜力不足以证明更高的市销率。除非这些条件改善，否则它们将继续对股价形成障碍。</p>
<p>始终需要考虑投资风险的潜在威胁。我们已经识别出 <strong>Cresco Labs 的两个警告信号</strong>，理解这些应该成为你投资过程的一部分。</p>
<p>如果你对盈利的强大公司感兴趣，那么你会想查看这份 <strong>免费的</strong> 有趣公司名单，这些公司交易的市盈率较低（但已证明它们能够实现盈利增长）。</p>

CRLBF

<p>Cresco Labs Inc. (CSE:CL) 的股价在过去 30 天内下跌了 37%，反映出收入表现不佳和有限的增长前景。该公司的市销率为 0.4 倍，低于行业水平，显示出投资者的担忧。分析师预测 Cresco Labs 的增长有限，这导致其股票估值下降。由于收入趋势疲软以及与行业相比的较低增长预期，投资者变得谨慎</p>

<p>Unfortunately for some shareholders, the <strong>Cresco Labs Inc.</strong> (CSE:CL) share price has dived 37% in the last thirty days, prolonging recent pain. The drop over the last 30 days has capped off a tough year for shareholders, with the share price down 37% in that time.</p>
<div class="lb-trans"><p>不幸的是，对于一些股东来说，<strong>Cresco Labs Inc.</strong>（CSE:CL）的股价在过去三十天内暴跌了 37%，延续了近期的痛苦。在过去的 30 天里，股价的下跌使得股东们经历了艰难的一年，股价在此期间下跌了 37%。</p>
</div><p>Following the heavy fall in price, Cresco Labs may be sending bullish signals at the moment with its price-to-sales (or &#34;P/S&#34;) ratio of 0.4x, since almost half of all companies in the Pharmaceuticals industry in Canada have P/S ratios greater than 1x and even P/S higher than 3x are not unusual. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/S.</p>
<div class="lb-trans"><p>在价格大幅下跌之后，Cresco Labs 目前可能发出看涨信号，其市销率（&#34;P/S&#34;）为 0.4 倍，因为在加拿大制药行业中，几乎一半的公司市销率超过 1 倍，甚至市销率高于 3 倍的情况也并不罕见。尽管如此，我们需要更深入地挖掘，以确定降低的市销率是否有合理的依据。</p>
</div><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p>
<div class="lb-trans"><p>特朗普承诺要&#34;释放&#34;美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
</div><p>See our latest analysis for Cresco Labs</p>
<div class="lb-trans"><p>查看我们对 Cresco Labs 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/273639073-ps-multiple-vs-industry-1-dark-2/1764162132640" alt="" original-src="https://images.simplywall.st/asset/chart/273639073-ps-multiple-vs-industry-1-dark-2/1764162132640"/></p>
<p>CNSX:CL Price to Sales Ratio vs Industry November 26th 2025</p>
<div class="lb-trans"><p>CNSX:CL 市销率与行业比较 2025 年 11 月 26 日</p>
</div><h3>How Has Cresco Labs Performed Recently?</h3>
<div class="lb-trans"><h3>Cresco Labs 最近的表现如何？</h3>
</div><p>While the industry has experienced revenue growth lately, Cresco Labs' revenue has gone into reverse gear, which is not great. The P/S ratio is probably low because investors think this poor revenue performance isn't going to get any better. If you still like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.</p>
<div class="lb-trans"><p>尽管该行业最近经历了收入增长，但 Cresco Labs 的收入却出现了下滑，这并不好。市销率可能较低是因为投资者认为这种糟糕的收入表现不会有所改善。如果你仍然喜欢这家公司，你会希望情况不是这样，以便你可以在它不受欢迎时买入一些股票。</p>
</div><p>Want the full picture on analyst estimates for the company? Then our <strong>free</strong> report on Cresco Labs will help you uncover what's on the horizon.</p>
<div class="lb-trans"><p>想要了解分析师对公司的完整预测吗？那么我们 <strong>免费的</strong>Cresco Labs 报告将帮助你揭示未来的趋势。</p>
</div><h2>Is There Any Revenue Growth Forecasted For Cresco Labs?</h2>
<div class="lb-trans"><h2>Cresco Labs 是否有收入增长的预测？</h2>
</div><p>Cresco Labs' P/S ratio would be typical for a company that's only expected to deliver limited growth, and importantly, perform worse than the industry.</p>
<div class="lb-trans"><p>Cresco Labs 的市销率对于一家预计仅能实现有限增长的公司来说是典型的，重要的是，其表现还低于行业水平。</p>
</div><p>In reviewing the last year of financials, we were disheartened to see the company's revenues fell to the tune of 9.8%. The last three years don't look nice either as the company has shrunk revenue by 21% in aggregate. Therefore, it's fair to say the revenue growth recently has been undesirable for the company.</p>
<div class="lb-trans"><p>在回顾过去一年的财务数据时，我们感到沮丧，因为公司的收入下降了 9.8%。过去三年的表现也不理想，因为公司总共缩减了 21% 的收入。因此，可以公平地说，最近的收入增长对公司来说是不可取的。</p>
</div><p>Turning to the outlook, the next three years should generate growth of 0.4% each year as estimated by the eight analysts watching the company. Meanwhile, the rest of the industry is forecast to expand by 5.8% per year, which is noticeably more attractive.</p>
<div class="lb-trans"><p>展望未来，预计未来三年每年将实现 0.4% 的增长，这是八位分析师对公司的估计。同时，行业的其余部分预计每年将扩张 5.8%，这显然更具吸引力。</p>
</div><p>With this information, we can see why Cresco Labs is trading at a P/S lower than the industry. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.</p>
<div class="lb-trans"><p>根据这些信息，我们可以理解为什么 Cresco Labs 的市销率低于行业水平。似乎大多数投资者预计未来增长有限，因此只愿意为该股票支付较低的价格。</p>
</div><h2>What We Can Learn From Cresco Labs' P/S?</h2>
<div class="lb-trans"><h2>我们可以从 Cresco Labs 的市销率中学到什么？</h2>
</div><p>Cresco Labs' P/S has taken a dip along with its share price. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.</p>
<div class="lb-trans"><p>Cresco Labs 的市销率随着其股价的下跌而下降。一般来说，我们倾向于将市销率的使用限制在评估市场对公司整体健康状况的看法上。</p>
</div><p>We've established that Cresco Labs maintains its low P/S on the weakness of its forecast growth being lower than the wider industry, as expected. At this stage investors feel the potential for an improvement in revenue isn't great enough to justify a higher P/S ratio. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.</p>
<div class="lb-trans"><p>我们已经确定 Cresco Labs 维持其低市销率是因为其预测增长低于更广泛的行业，正如预期的那样。在这个阶段，投资者认为收入改善的潜力不足以证明更高的市销率。除非这些条件改善，否则它们将继续对股价形成障碍。</p>
</div><p>It's always necessary to consider the ever-present spectre of investment risk. We've identified <strong>2 warning signs with Cresco Labs</strong>, and understanding these should be part of your investment process.</p>
<div class="lb-trans"><p>始终需要考虑投资风险的潜在威胁。我们已经识别出 <strong>Cresco Labs 的两个警告信号</strong>，理解这些应该成为你投资过程的一部分。</p>
</div><p>If strong companies turning a profit tickle your fancy, then you'll want to check out this <strong>free</strong> list of interesting companies that trade on a low P/E (but have proven they can grow earnings).</p>
<div class="lb-trans"><p>如果你对盈利的强大公司感兴趣，那么你会想查看这份 <strong>免费的</strong> 有趣公司名单，这些公司交易的市盈率较低（但已证明它们能够实现盈利增长）。</p>
</div>

Cresco Labs Inc. (CSE:CL) 对于某些投资者而言表现不佳，其股价下跌了 37%